🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06640153
Active, not recruiting Observational

MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma

NCT06640153 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Observational
Started
2024-08-21
Last updated
2024-10-15

Condition(s) studied

Gastric Cancer, Gastroesophageal Junction Cancer

Investigational drug(s) / intervention(s)

mpMRI

mpMRI: Gastroesophageal junction or upper gastric adenocarcinoma patients undergo mpMRI at siewert classification, length of esophageal involvement, primary staging and restaging

Study summary

Accurate preoperative Siewert classification, precise assessment of the extent of esophageal involvement, and staging is crucial for determining the appropriate surgical approach and achieving negative resection margins. The purpose of this study is to investigate the diagnostic performance of the Multi-parametric magnetic resonance imaging (mpMRI) and computed tomography (CT) in gastroesophageal junction and upper gastric cancers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: 1. patients with gastric cancer confirmed by preoperative gastroscopic biopsy; 2. underwent standardized mpMRI and CT examination; 3. patients with complete postoperative pathological data and pathological results of gastroesophageal Junction or upper gastric adenocarcinoma; Exclusion Criteria: 1. combined with other tumors; 2. Clinical and imaging data were missing or could not meet the research needs; 3. the location of lesions could not be determined;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu

More The First Affiliated Hospital with Nanjing Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06640153 on ClinicalTrials.gov ↗ ← All trials in China